Year: 2024

Parkinson’s Drug Found to Promote Pathogenic Gut Bacteria

Fig. 1: Chemical imaging of active gut microbes. After brief incubation with heavy water, culture medium and a drug, various chemical bonds (here C-D and C-H) in the stool sample are shown in yellow and green, their ratio in yellow-purple (left). Selected microbes are detected in the same image section with fluorescence-labelled oligonucleotide probes in cyan. The activity of the detected microbes can be determined based on the amount of C-D bonds. C: Xiaowei Ge (Boston University)

An international team of scientists have revealed that the widely prescribed Parkinson’s disease drug entacapone significantly disrupts the human gut microbiome by inducing iron deficiency. This international study, provides new insights into the often-overlooked impact of human-targeted drugs on the microbial communities that play a critical role in human health. The findings, published in Nature Microbiology, suggest however that iron supplementation can help counteract these impacts.

While it is well established that antibiotics can significantly disrupt the human gut microbiome, emerging research shows that a wide range of human-targeted drugs – particularly those used to treat neurological conditions – can also profoundly affect the microbial communities living in our bodies. Despite their intended therapeutic effects on different organs, these drugs can inadvertently disrupt the balance of gut microbes, leading to potential health consequences. Until now, most studies investigating these interactions relied either on patient cohort analyses affected by many confounding factors or on experiments using isolated gut bacteria, which do not fully capture the complexity of the human microbiome.

Investigating drug–bug interactions

The team, which included some from the University of Vienna, used a novel experimental approach. The researchers studied the effects of two drugs – entacapone and loxapine, a medication for schizophrenia – on faecal samples from healthy human donors. They incubated the samples with therapeutic concentrations of these drugs, then analysed the impact on the microbial communities using advanced molecular and imaging techniques, including heavy water labelling combined with Stimulated Raman Spectroscopy (SRS). The team discovered that loxapine and even more so entacapone severely inhibited many microbiome members, while E. coli dramatically expanded in the presence of entacapone.

“The results were even more striking when we examined microbial activity, rather than just their abundance,” explained Fatima Pereira, lead author of the study and former Postdoctoral researcher at the University of Vienna. “The heavy water-SRS method allowed us to observe the subtle yet significant changes in the gut microbiome, which are often missed in traditional abundance-based measurements.”

Entacapone induces iron starvation, favours pathogenic microbes

The researchers hypothesised that entacapone might interfere with iron availability in the gut, a crucial resource for many microbes. Their experiments confirmed that adding iron to faecal samples containing entacapone counteracted the drug’s microbiome-altering effects. Further investigation revealed that E. coli, which thrived under these conditions, carried a highly efficient iron-uptake system (enterobactin siderophore). This system allowed the bacteria to overcome iron starvation and proliferate, even in the presence of the drug.

“By showing that entacapone induces iron deficiency, we have uncovered a new mechanism of drug-induced gut dysbiosis, in which the drug selects for E. coli and other potentially pathogenic microbes well adapted to iron limiting conditions,” said Michael Wagner, scientific director of the Excellence Cluster and vice-head of the Centre for Microbiology and Environmental Systems Science (CeMESS) at the University of Vienna.

Wider implications for drug–microbiome interactions

This discovery has broader implications for understanding how other human-targeted drugs might affect the gut microbiome. Several drugs, including entacapone, contain metal-binding catechol groups, suggesting that this mechanism could be a more common pathway for drug-induced microbiome alterations.

The findings also present an opportunity to mitigate the side effects of drugs like entacapone. By ensuring sufficient iron availability to the large intestine, it may be possible to reduce dysbiosis and the gastrointestinal issues that often accompany Parkinson’s disease treatment.

“The next step is to explore how we can modify drug treatments to better support the gut microbiome,” said Wagner. “We are looking at strategies to selectively deliver iron to the large intestine, where it can benefit the microbiome without interfering with drug absorption in the small intestine.”

Source: University of Vienna

Bayer Issues Recall on YAZ Plus Contraceptive Pills

Photos supplied by Bayer showing the affected blister (left) and the normal blister (right).

On November 21, Bayer (Pty) Ltd issued a medicine recall for a specific batch (WEW96J) of YAZ PLUS tablets. In a press release, they explain the reason for the recall: it has been discovered that the active and inactive tablets in this batch are swapped. This mix-up has resulted in some packs containing only four hormone tablets instead of the required 24, and 24 hormone-free tablets instead of four, compromising the product’s contraceptive efficacy.

The company advises that healthcare professionals, wholesalers, hospitals, retail pharmacy outlets, doctors, nurses, pharmacists, authorised prescribers, dispensers, and individual customers or patients in possession of the affected batch can return product to their healthcare facility from which it was dispensed, for credit.

Bayer urges that if you are in possession of YAZ PLUS tablets from the affected batch, to do the following:

  1. Stop Use Immediately: If you have been taking the tablets from a batch that is affected with the mix-
    up, stop taking them immediately and contact your healthcare professional. While only a limited number of packs from the respective batch is affected, as a precautionary measure, no tablets from these packs shall be used until you have consulted your Healthcare Practitioner, as they may potentially not provide the contraceptive protection you expect.
  2. Return the Product: Please return any affected packs to the pharmacy or retailer where you
    purchased them for a replacement or refund.
  3. Check Your Packs: If you have multiple packs of YAZ PLUS, please check each one of them, to
    ensure they are not from the affected batch.
  4. Consult Healthcare Provider: If you have consumed tablets from the affected batch, or if you have
    concerns about your contraceptive coverage, please consult your healthcare provider as soon as
    possible for advice.

In the press release, Bayer says that it “takes the safety and efficacy of its products seriously and is committed to ensuring that all YAZ PLUS tablets in the market meet the highest quality standards.” It further advises that the root cause for the mix-up of tablets in the packaging has been identified and corrective measures taken. Only this one batch – and no others – was affected.

“The company is working diligently with SAHPRA and healthcare providers to facilitate the recall process and minimise any inconvenience to our customers. We are dedicated to addressing this issue promptly and ensuring the continued health and safety of all our customers.”

Further Information and Support:
For more information about this recall, or if you have any questions or concerns, please contact Bayer +27
(0) 11 921 5000. Our team is available to provide the support and information you need.
Report a side effect: Patient Safety Reporting – Introduction
Report a product quality complaint for Pharmaceutical Products: afptc@bayer.com

Short-term Menopausal Hormone Therapy has no Long-term Cognitive Impact

Photo by Teona Swift on Unsplash

Women in early postmenopause taking short-term MHT had no cognitive effects a decade later

Short-term menopausal hormone therapy (MHT) did not have long-term cognitive effects when given to women in early postmenopause, according to a study published November 21st in the open-access journal PLOS Medicine by Carey Gleason from the University of Wisconsin-Madison, USA, and colleagues.

While MHT can offer relief from the challenging symptoms of menopause, many women and doctors are hesitant to start MHT due to safety concerns. Previous research has linked one form of hormone therapy to mild cognitive impairment and dementia in women older than 65 years of age, prompting research on the importance of age and timing of therapy on cognitive impairment. Other studies have suggested that transdermal oestrogen may have long-term cognitive benefits.

In the Kronos Early Estrogen Prevention Study (KEEPS), women in early postmenopause with good cardiovascular health were randomised to receive one of two types of MHT (oral or transdermal oestrogen) or placebo. At the end of four years, no cognitive benefit or harm was seen in those who received MHT compared to the placebo group. However, long-term cognitive effects of MHT are still understudied.

In this new follow-up study – the KEEPS Continuation Study – researchers revisited participants nearly ten years later to repeat a series of cognitive tests. Among 275 women, although MTH failed to protect against cognitive decline, short-term MHT also had no long-term negative cognitive impact.

These findings may offer reassurance to women considering MHT while adding to the growing body of research supporting the importance of timing for MHT. More research is needed to investigate whether these results are generalisable to women with higher cardiovascular risk.

The authors add, “For women in menopause and the health care providers caring for them, getting direct, clear and evidence-based information about menopausal hormone therapy is challenging. And they need data to guide their decisions.”

Provided by PLOS

Workouts – or Disturbed Sleep – Impact Brain Activity Weeks Later

Photo by Ketut Subiyanto on Pexels

In a rare, longitudinal study, researchers from Aalto University and the University of Oulu tracked one person’s brain and behavioural activity for five months using brain scans and data from wearable devices and smartphones. The results appear in PLOS Biology.

“We wanted to go beyond isolated events,” says research leader (and study participant) Ana Triana. “Our behaviour and mental states are constantly shaped by our environment and experiences. Yet, we know little about the response of brain functional connectivity to environmental, physiological, and behavioural changes on different timescales, from days to months.”

The study found that the brain does not respond to daily life in immediate, isolated bursts. Instead, brain activity evolves in response to sleep patterns, physical activity, mood, and respiration rate over many days. This suggests that even a workout or a restless night from last week could still affect the brain – and therefore attention, cognition and memory – well into next week.

The research also revealed a strong link between heart rate variability – a measure of the heart’s adaptability – and brain connectivity, particularly during rest. This suggests that impacts on the body’s relaxation response, like stress management techniques, could shape brain wiring even when not actively concentrating on a task. Physical activity was also found to positively influence the way brain regions interact, potentially impacting memory and cognitive flexibility. Even subtle shifts in mood and heart rate left lasting imprints for up to 15 days.

Study goes beyond a snapshot

The research is unusual in that few brain studies involve detailed monitoring over days and weeks. “The use of wearable technology was crucial,” says Triana. “Brain scans are useful tools, but a snapshot of someone lying still for half an hour can only show so much. Our brains do not work in isolation.”

Triana was herself the subject of the research, monitored as she went about her daily life. Her unique role as both lead author and study participant added complexity, but also brought firsthand insights into how best to maintain research integrity over several months of personalised data collection.  Data from the devices and twice-weekly brain scans were complemented by qualitative data from mood surveys. 

The researchers identified two distinct response patterns: a short-term wave lasting under seven days and a long-term wave up to 15 days. The former reflects rapid adaptations, like how focus is impacted by poor sleep, but it recovers quickly. The long wave suggests more gradual, lasting effects, particularly in areas tied to attention and memory. 

Single-subject studies offer opportunities for improving mental health care 

The researchers hope their innovative approach will inspire future studies that combine brain data with everyday life to help personalise mental health treatment. 

“We must bring data from daily life into the lab to see the full picture of how our habits shape the brain, but surveys can be tiring and inaccurate,” says study co-author, neuroscientist and physician Dr Nick Hayward. “Combining concurrent physiology with repeated brain scans in one person is crucial. Our approach gives context to neuroscience and delivers very fine detail to our understanding of the brain.”

The study is also a proof-of-concept for patient research. Tracking brain changes in real time could help detect neurological disorders early, especially mental health conditions where subtle signs might be missed.

“Linking brain activity with physiological and environmental data could revolutionise personalised healthcare, opening doors for earlier interventions and better outcomes,” says Triana.

Source: Aalto University

Human Hearts may Possess a Latent Ability to Regenerate Cardiomyocytes

Right side heart failure. Credit: Scientific Animations CC4.0

After severe heart failure, the ability of the heart to heal by forming new cells is very low. But now Karolinska Institutet researchers found that, after use of a supportive heart pump, the capacity of a damaged heart to repair itself with new cardiomyocytes becomes significantly higher – even greater than that of a healthy heart. This study is published in the journal Circulation.

The ability of the human heart to renew itself by regenerating its muscle cells, myocytes, is very limited. But what happens to this capability when the heart is damaged by severe heart failure has been unknown.

Researchers at Karolinska Institutet have now discovered that after an injury, the rate of cell renewal is even lower than in a healthy heart. Standard-of-care for patients with advanced heart failure is a surgically implanted pump that helps propel blood, a so-called left ventricular assist device (LVAD).

Kick-starting repair

Surprisingly, the researchers found that patients with such a heart pump, who have shown significant improvement in their heart function, can regenerate heart muscle cells at a rate more than six times higher than in healthy hearts.

“The results suggest that there might be a hidden key to kick-start the heart’s own repair mechanism”, says Olaf Bergmann, senior researcher at the Department of Cell and Molecular Biology at Karolinska Institutet and last author of the paper.

The mechanism behind the effect is still unknown and there is not yet any hypothesis to explain it.

“It is difficult to say. In the existing data we cannot find an explanation for the effect, but we will now continue to study this process at a cellular and molecular level,” says Olaf Bergmann.

The findings open the possibility of developing new therapies for patients with serious heart conditions that stimulate the heart’s ability to repair itself after damage. This way, patients wouldn’t have to rely only on heart transplants or other kinds of long-term mechanical support.

“This offers some hope that the recovery after a heart incident can somehow be boosted,” says Olaf Bergmann.

Atomic bombs enable cell age estimation

It is generally difficult to determine the age of cells in the human body and to decide which cells are new and which are old. However, by using a method earlier devised by Jonas Frisén, professor of stem cell research at Karolinska Institutet, the group has been able to count the rate of renewal of myocytes in the heart. The method is based upon the fact that the percentage of radioactive carbon in the atmosphere, and subsequently in our cells, has steadily decreased since the nuclear test ban in 1963. For every following year, there is a little less radioactivity in newly formed cells, which means that they can be ‘dated’. 

Source: Karolinska Institute

Tirzepatide Found to Protect against Worsening Heart Failure

Right side heart failure. Credit: Scientific Animations CC4.0

The diabetes drug tirzepatide can reduce the risk of death or worsening heart failure for patients with heart failure, preserved heart pump function and obesity, new research from UVA Health reveals.

Researchers tested the GLP-1 receptor agonist in the SUMMIT clinical trial, where a total of 731 patients with diastolic heart failure and a body mass index (BMI) of 30 or above were randomised to receive injections of either tirzepatide or a harmless placebo. The researchers then followed the patients for a median period of two years. Tirzepatide is also prescribed as a weight loss drug in certain countries.

During that time, 56 placebo recipients died or suffered worsening heart failure, compared with only 36 of those receiving tirzepatide. Participants taking tirzepatide also lost 11.6% of their body weight.

“This class of drugs continue to show benefits far beyond weight loss,” said researcher Christopher Kramer, MD, chief of UVA Health’s Division of Cardiovascular Medicine. “This drug will become an important part of the armamentarium for patients with obesity-related heart failure and preserved heart function.”

Obesity and heart failure

Obesity is a major contributing factor to heart failure, so Kramer and his collaborators in the SUMMIT trial wanted to see if tirzepatide, a weight-loss drug already approved by the federal Food and Drug Administration, could help. 

The trial found that tirzepatide offered substantial benefits for managing diastolic heart failure, reducing deaths, preventing hospitalizations and generally benefiting recipients’ health and quality of life. For example, recipients saw improvements in how far they could walk in six minutes, as well as substantial decreases in a biological indictor used to measure inflammation and predict risk of serious cardiovascular events.

Side effects seen in the tirzepatide group consisted of gastrointestinal issues such as nausea and diarrhea, and these were mostly mild or moderate, the researchers reported Saturday at a meeting of the American Heart Association in Chicago.

Tirzepatide Findings

Kramer, a cardiovascular imager, also led a magnetic resonance imaging substudy looking at how tirzepatide affected recipients’ heart structure and function. The researchers found beneficial reductions in both left ventricular mass (weight of the heart) and in the amount of surrounding fat tissue. The reduction in LV mass correlated with the reduction in body weight, as well as with decreases in left ventricular volumes.

“This drug is reversing the abnormal properties of the heart brought on by obesity,” Kramer said. “There is much more to these drugs than weight loss alone.”

The findings from these studies by Kramer and his fellow researchers from SUMMIT are being published simultaneous with the American Heart meeting in Chicago in four separate manuscripts, including the New England Journal of Medicine, Nature Medicine, Circulation and the Journal of the American College of Cardiology.

Source: University of Virginia Health System

Researcher Discovers Ancient Egyptian Mugs Contained Hallucinogens

(a) Drinking vessel in shape of Bes head; El-Fayūm Oasis, Egypt; Ptolemaic-Roman period (4th century BCE − 3rd century CE), (courtesy of the Tampa Museum of Art, Florida). (b) Bes mug from the Ghalioungui collection, 10.7 × 7.9 cm (Ghalioungui, G. Wagner 1974, Kaiser 2003, cat. no. 342). (c) Bes mug inv. no. 14.415 from the Allard Pierson Museum, 11.5 × 9.3 cm (courtesy of the Allard Pierson Museum, Amsterdam; photo by Stephan van der Linden). (d) Bes mug from El-Fayum, dimensions unknown (Kaufmann 1913; Kaiser 2003, cat. no. 343). Credit: Scientific Reports, 2024

The first-ever physical evidence of hallucinogens in an Egyptian mug has been found, validating written records and centuries-old myths of ancient Egyptian rituals and practices. Through advanced chemical analyses, University of South Florida professor Davide Tanasi examined one of the world’s few remaining Egyptian Bes mugs.

Such mugs, including the one donated to the Tampa Museum of Art in 1984, are decorated with the head of Bes, an ancient Egyptian god or guardian demon worshiped for protection, fertility, medicinal healing and magical purification. Published in Nature’s Scientific Reports, the study sheds light on an ancient Egyptian mystery: The secret of how Bes mugs were used about 2000 years ago. 

“There’s no research out there that has ever found what we found in this study,” Tanasi said. “For the first time, we were able to identify all the chemical signatures of the components of the liquid concoction contained in the Tampa Museum of Art’s Bes mug, including the plants used by Egyptians, all of which have psychotropic and medicinal properties.”

The presence of Bes mugs in different contexts over a long period of time made it extremely difficult to speculate on their contents or roles in ancient Egyptian culture.

“For a very long time now, Egyptologists have been speculating what mugs with the head of Bes could have been used for, and for what kind of beverage, like sacred water, milk, wine or beer,” said Branko van Oppen, curator of Greek and Roman art at the Tampa Museum of Art. “Experts did not know if these mugs were used in daily life, for religious purposes or in magic rituals.”

Several theories about the mugs and vases were formulated on myths, but few of them were ever tested to reveal their exact ingredients until the truth was extracted layer by layer.

Tanasi, who developed this study as part of the Mediterranean Diet Archaeology project promoted by the USF Institute for the Advanced Study of Culture and the Environment, collaborated with several USF researchers and partners in Italy at the University of Trieste and the University of Milan to perform chemical and DNA analyses. With a pulverised sample from scraping the inner walls of the vase, the team combined numerous analytical techniques for the first time to uncover what the mug last held.

The new tactic was successful and revealed the vase had a cocktail of psychedelic drugs, bodily fluids and alcohol – a combination that Tanasi believes was used in a magical ritual re-enacting an Egyptian myth, likely for fertility. The concoction was flavoured with honey, sesame seeds, pine nuts, liquorice and grapes, which were commonly used to make the beverage look like blood.

“This research teaches us about magic rituals in the Greco-Roman period in Egypt,” Van Oppen said. “Egyptologists believe that people visited the so-called Bes Chambers at Saqqara when they wished to confirm a successful pregnancy because pregnancies in the ancient world were fraught with dangers. So, this combination of ingredients may have been used in a dream-vision inducing magic ritual within the context of this dangerous period of childbirth.”

“Religion is one of the most fascinating and puzzling aspects of ancient civilizations,” Tanasi said. “With this study, we’ve found scientific proof that the Egyptian myths have some kind of truth and it helps us shed light on the poorly understood rituals that were likely carried out in the Bes Chambers in Saqqara, near the Great Pyramids at Giza.”

The Bes mug is on display now at the Tampa Museum of Art and can be viewed in the exhibition, “Prelude: An Introduction to the Permanent Collection.” View a 3D model of the Bes mug produced by the USF Institute for Digital Exploration.

Many not Getting Enough Nutrients in Their Pregnancy, Study Finds

Source: Pixabay CC0

It’s generally estimated that around 10% of pregnant people struggle to meet their nutritional needs – but the real number could be far higher, according to new research in The Journal of Nutrition.

Over 90% of pregnant individuals are potentially failing to get enough iron, vitamin D, or vitamin E from the food they eat, while over one-third could be short of calcium, vitamin C, and vitamin A. Troublingly, almost two-thirds of pregnant people were also found to be getting insufficient dietary folate – a critical nutrient that helps prevent birth defects in the baby’s brain and spine.

“It’s important to remember that many pregnant people take prenatal vitamin supplements, which might help prevent nutritional deficiencies,” says lead author Dr Samantha Kleinberg, professor at Stevens Institute of Technology. “Nonetheless, this is a startling finding that suggests we need to be looking much more closely at whether pregnant individuals are getting the nutrients they need.”

Where most previous studies of nutrition during pregnancy relied on a few days of food diaries, or on simply asking people what they remembered eating, the Stevens team asked pregnant people to take before-and-after photos of everything they ate over two 14-day periods. Experts then reviewed the photos to assess the amount of food actually eaten and determine the nutrients consumed during each meal.

That’s a far more accurate approach, because people are notoriously bad at estimating portion size or accurately reporting what they’ve eaten, Dr Kleinberg explains. A photo-based approach is also much less laborious for pregnant people, making it easy to collect data over a period of weeks instead of just a few days.

“Most surveys only track diet over a day or two – but if you feel off one day and don’t eat much, or have a big celebratory meal over the weekend, that can skew the data,” Dr Kleinberg says. “By looking at a longer time period, and using photos to track diet and nutrition, we’re able to get a much richer and more precise picture of what people actually ate.”

The study found significant dietary variations between individuals, but also among the same individuals from one day to the next, suggesting that shorter studies and population-based reports might be failing to spot important nutritional deficits. “Some people eat really well, and others don’t – so if you just take an average, it looks like everything’s fine,” Dr Kleinberg explains. “This study suggests that in reality, an alarming number of pregnant people may not be getting the nutrients they need from their food.”

Using food photos also recorded the exact timing of meals and snacks, and to explore the way that patterns of eating behaviour correlated with total energy and nutrient intake. When pregnant people ate later in the day, the data shows, they were likely to consume significantly more total calories – potentially an important finding as researchers explore connections between eating behaviours and health problems such as gestational diabetes.

The current research didn’t directly study health outcomes, so it’s too early to say whether insufficient nutrition or excessive energy consumption is adversely impacting pregnant individuals or their babies. “We’ll be digging into that in future studies, and looking at possible connections with eating patterns and changes in glucose tolerance,” Dr Kleinberg says.

Source: Stevens Institute of Technology

New Study Investigates How Jetlag can Disrupt Metabolism

Photo by Andrea Piacquadio: https://www.pexels.com/photo/young-man-in-sleepwear-suffering-from-headache-in-morning-3771115/

A new study from the University of Surrey and the University of Aberdeen has found that disruptions to our body clock, such as those experienced during jetlag, impact our metabolism – but to a lesser extent than sleepiness and the primary clock in the brain. 

Led by Professor Jonathan Johnston at the University of Surrey and Professor Alexandra Johnstone at the University of Aberdeen, the research involved a controlled experiment where participants experienced a 5-hour delay in their bedtime and mealtimes.  

The study, published on iScience, highlights that the time shifts lead to: 

  • Reduced energy spent processing meals. 
  • Changes in blood sugar and fat levels. 
  • Slower release of breakfast contents from the stomach. 

These metabolic effects were temporary, however, and mostly recovered within 2-3 days of the 5-hour time delay. This was in marked contrast to the main clock in the brain, plus feelings of sleepiness and alertness, which had not recovered within 5 days of the 5-hour time delay. 

Our research underscores the importance of maintaining a consistent sleep schedule, particularly in our fast-paced world in which long trips and shift work are ever so common. Even a small time shift can impact many aspects of metabolism, but it now seems that metabolic consequences of jetlag recover far more quickly than impairment of sleep and alertness. Understanding the impact of circadian rhythms on our health can help us make informed choices about our lifestyle. By optimising our sleep and eating patterns, we can improve our overall wellbeing. 

Professor Jonathan Johnston, Professor of Chronobiology and Integrative Physiology

Source: University of Surrey

Long-term Study Finds Link between Earlier Diabetes Diagnosis and Dementia Risk

Photo by Nataliya Vaitkevich on Pexels

People diagnosed with type 2 diabetes at a younger age are at a higher risk for developing dementia than those diagnosed later in life, according to a study led by researchers at the NYU Rory Meyers College of Nursing. The findings, published in PLOS ONE, show that the increased risk is especially pronounced among adults with obesity.

“Our study suggests that there may be cognitive consequences to earlier onset type 2 diabetes, and it points to the need for strategies to prevent dementia that consider both diabetes and obesity,” said Xiang Qi, assistant professor at NYU Meyers and the study’s first author.

Type 2 diabetes is a known risk factor for dementia. Although the underlying mechanisms are not fully understood, scientists think that some of the hallmarks of diabetes, such as high blood sugar, insulin resistance, and inflammation, may encourage the development of dementia in the brain.

While type 2 diabetes was once a disease of older adults, it is increasingly prevalent among younger individuals: one in five people with type 2 diabetes worldwide is under 40 years old.

To understand how the timing of a type 2 diabetes diagnosis relates to dementia risk, the research team analyzed data from 2002 to 2016 in the Health and Retirement Study, a longitudinal study conducted by the University of Michigan Institute for Social Research. The PLOS ONE study included 1213 US adults aged 50 and over with type 2 diabetes confirmed by blood tests, without dementia at baseline. Following participants for up to 14 years, 216 (17.8%) developed dementia based on follow-up telephone interviews.

The researchers found that adults diagnosed with type 2 diabetes at younger ages were at increased risk for developing dementia, compared to those diagnosed at 70 years or older. Adults diagnosed with diabetes before age 50 were 1.9 times as likely to develop dementia as those diagnosed at 70 and older, while those diagnosed between 50–59 years were 1.72 times as likely and those diagnosed between 60–69 years were 1.7 times as likely.

Using linear trend tests, the researchers found a graded association between age at diagnosis and dementia risk: for each year younger a person is at the time of their type 2 diabetes diagnosis, their risk for developing dementia increases by 1.9%.

“While we do not know for sure why an earlier diabetes diagnosis would increase the risk for dementia, prior studies show that people diagnosed with type 2 diabetes in mid-life may experience more vascular complications, poor blood sugar control, and insulin resistance – all of which are known risk factors for cognitive impairment,” said Bei Wu, the Dean’s Professor in Global Health and vice dean for research at NYU Meyers and the study’s senior author.

In addition, obesity appeared to influence the relationship between type 2 diabetes and dementia. Individuals with obesity who were diagnosed with type 2 diabetes before age 50 had the highest dementia risk in the study.

The researchers note that this greater understanding of the connection between diabetes onset, obesity, and dementia may help inform targeted interventions to prevent dementia.

“Our study highlights the importance of one’s age at diabetes diagnosis and suggests that specifically targeting obesity – whether through diet and exercise or perhaps medication – may play a role in staving off dementia in younger adults with diabetes,” said Wu.

Source: New York University